$GALT

$3.38 +$0.19 (5.96%) Close

$GALT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 100.8M shares outstanding

Who owns GALT?

By type of holder

Institutions 15.3% Insiders 84.7% Everyone else 0.0%

Concentration Top 10 holders own 111.6%

Richard E. Uihlein 54.2% · Czirr James C 46.3%

Institutional ownership

15.3%

+1.5 pts vs last qtr

Institutional holders

-3 vs last qtr

Net shares bought

+1.5M

by institutions in Q2 2026

New / sold out

20 / 23

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

BlackRock, Inc. +2.2M
Geode Capital Management, LLC +695.6K

Biggest sellers in Q2 2026

Millennium Management LLC −762.6K
Susquehanna International Group, LLP SOLD OUT −555.7K

Who is planning to sell?

Notices of proposed sale, last 12 months

$5.75M

17 notices from 6 people

Shares covered

1.2M

1.16% of the company

Arranged in advance

100%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Shlevin Harold H. Director 10b5-1 $1.84M
Jamil Khurram Officer 10b5-1 $1.46M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+12.1%

+2.30% a year

Each share's claim on the business

−10.8%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $13.1M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years67% 3–5 years9% 1–3 years13% Under 1 year11%

Quarterly turnover

31.0%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting GALT on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
B BlackRock, Inc.	3.0M	2.96%	+2.2M (+273.9%)	≤2021	0.0%
Shares held by quarter Peak holding3.0M (Q2'26) Change over 8 quarters+1.4M Share of the company2.960% BlackRock, Inc.'s full portfolio →
VC Vanguard Capital Management LLC	2.2M	2.15%	+201.5K (+10.2%)	≤2021	0.0%
Shares held by quarter Peak holding2.2M (Q2'26) Change over 8 quarters+2.2M Share of the company2.150% Vanguard Capital Management LLC's full portfolio →

BlackRock, Inc.

3.0M

% of company

2.96%

Change vs last qtr

+2.2M (+273.9%)

Held since

≤2021

Vanguard Capital Management LLC

2.2M

% of company

2.15%

Change vs last qtr

+201.5K (+10.2%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding Galectin Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting GALT on Form N-PORT; together they hold 5.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$7.06M	1.5M	1.51%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$4.41M	951.5K	0.94%	0.01%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$7.06M

% of company

1.51%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$4.41M

% of company

0.94%

% of the fund

0.01%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Galectin Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RE Richard E. Uihlein 5%+ holder 13D · 49.3%	54.7M	54.21%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company54.210% Disclosed stake13D · 49.3% View the 13D/G filing →
CJ Czirr James C Insider	46.7M	46.31%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company46.310% Czirr James C's insider activity →

Richard E. Uihlein

5%+ holder13D · 49.3%

54.7M

% of company

54.21%

Change vs last qtr

—

Held since

—

Czirr James C

Insider

46.7M

% of company

46.31%

Change vs last qtr

—

Held since

—

6 more holders behind a free account

See every insider and 5%+ holder of Galectin Therapeutics Inc.

Comments